Background {#Sec1}
==========

Chronic obstructive pulmonary disease (COPD) is a worldwide disease with a high mortality and morbidity burden and will become the third leading cause of worldwide death in 2030 \[[@CR1]\]. Acute exacerbation of COPD (AECOPD) is defined as an acute worsening of respiratory symptoms, which is associated with the decline of patients' health statuses and lung function and can even increase the risk of death \[[@CR2], [@CR3]\]. Pharmacological interventions that are recommended in the clinical guidelines have exhibited effects on preventing and managing exacerbations. Unfortunately, AECOPD still occurs frequently, and death is a common outcome for hospitalized patients \[[@CR4]\]. Thus, further treatment strategies, including integrated Chinese medicine and routine pharmacology (RP), are still urgently needed for AECOPD management.

Chinese herbal medicine has been used to manage respiratory diseases for thousands of years and is commonly prescribed in clinical practice for use in combination with western medicine techniques for patients with AECOPD. Various strategies are recommended in the Chinese clinical guidelines \[[@CR5]--[@CR7]\], including the use of six commonly used Chinese herb formulas: the Weijing decoction (WJ), the Maxingshigan decoction (MXSG), the Yuebijiabanxia decoction (YBBX), the Qingqihuatan decoction (QQHT), the Dingchuan decoction (DC) and the Sangbaipi decoction (SBP). Previous systematic reviews have demonstrated the efficacies of each of the previously mentioned formulas \[[@CR8], [@CR9]\]. Additionally, mechanistic studies have revealed the anti-inflammation and antioxidative stress functions of these formulas and the active compounds of the herb ingredients \[[@CR10]--[@CR12]\]. However, it is still unknown which formula is superior when combined with routine pharmacotherapy.

As a new meta-analytic technique, a network meta-analysis can estimate both direct and indirect comparisons and can provide a ranking of optimal interventions \[[@CR13]--[@CR15]\]. Therefore, we conducted this systematic review and a network meta-analysis to provide a ranking of the frequently used Chinese formulas for the management of AECOPD.

Methods {#Sec2}
=======

The protocol of this study was registered on PERSPERO (CRD42016052699) and the full text was published elsewhere \[[@CR16]\]. We reported this review by following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) extension statement for network meta-analyses of health care interventions \[[@CR17]\] (Additional file [1](#MOESM1){ref-type="media"}).

Eligibility criteria {#Sec3}
--------------------

We included randomized controlled trials of patients with acute exacerbation of COPD that investigated the efficacies of six Chinese herb formulas combined with routine pharmacotherapy. Patients with AECOPD were confirmed to have the disorder via global standard diagnostic criteria and clinical symptoms \[[@CR18]\]. Intervention regimens consisted of pharmacotherapy combined with the following formulas: WJ, MXSG, YBBX, QQHT, DC and SBP. Studies were included in the analysis if they reported one or more of the following pre-defined outcomes. The primary outcomes were FEV1, PaO2, PaCO2 and length of hospital stay. The secondary outcomes included (1) dyspnoea; (2) health-related quality of life; (3) hospital readmission for acute exacerbation; (4) effective rate \[[@CR19]\]; and (5) adverse events. Studies were excluded if (1) a study included participants with complications of COPD, such as cor pulmonale or pulmonary hypertension or (2) data were unavailable.

Search strategy {#Sec4}
---------------

We searched PubMed, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, AMED, the Chinese Biomedical Database (CBM), the Chinese National Knowledge Infrastructure (CNKI), the Chongqing VIP information (CQVIP) and the Wanfang database from the starting dates of these databases to December 2016. Furthermore, the reference lists of the retrieved systematic reviews and the included studies were also screened. Language restrictions were not applied. The search terms are presented in Additional file [2](#MOESM2){ref-type="media"}.

Study selection and data extraction {#Sec5}
-----------------------------------

Two independent reviewers (JL and JZ) screened the titles and abstracts of the citations and evaluated the full texts according to the selection criteria. Any disagreement was resolved by discussion with a third reviewer (JC).

Data extraction was performed by using the Epidata software 3.1 with a pre-designed database sheet. The following variables were included for the analysis: first author, publication year, diagnosis information, disease duration, stage, sample size, age, details of the interventions, control, outcomes, treatment duration, follow-up period and adverse events.

Risk of bias assessment {#Sec6}
-----------------------

Two researchers (JL and JZ) independently evaluated the biases of the eligible studies by using the Cochrane collaboration of risk of bias tool. Six items (including randomization methods, allocation concealment, the blinding of participants and personnel, the blinding of the outcome assessors, incomplete outcome data, selective reporting and other sources of bias) were assessed, and any discrepancies were resolved by consensus.

Statistical analysis {#Sec7}
--------------------

We conducted a traditional, pair-wise meta-analysis using a random-effects model. For the continuous data, such as FEV1, mean differences were estimated, along with 95% confidence intervals (CIs), for the individual studies. Effective rates, as the dichotomous data, were reported with odds ratios (ORs) and 95%CIs. The chi-squared test and I^2^ test were used to assess the heterogeneity.

We conducted the NMA by using the Markov Chain Monte Carlo methods to compare the treatment effects of the six Chinese herb formulas. The posterior distribution was calculated by using 100,000 iterations, with a first burn-in of 20,000 iterations. The consistency between the direct and indirect comparisons was not determined because direct evidence was unavailable. The adjusted indirect comparisons were estimated with a 95% credible interval (95%CrI) for the dichotomous and continuous outcomes. To investigate the best interventions for the various treatments, a surface under the cumulative ranking curve (SUCRA) and mean ranks were performed for the main outcomes. We also generated a comparison-adjusted funnel plot to investigate the potential publication bias. The network meta-analysis was conducted by using the WinBUGS 1.4.3 software, and the main relative graphs were created by using Stata 13.1 software.

Results {#Sec8}
=======

Literature search and basic characteristics {#Sec9}
-------------------------------------------

The literature search identified a total of 1232 citations, and 55 studies involving 4560 participants met the eligible criteria and were included in the analyses (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR20]--[@CR74]\]. All of the included studies diagnosed the participants according to the Chinese COPD guidelines. Twenty-six of the included studies reported the severity of the condition at baseline, ranging from mild to very severe. The mean age of the patients with AECOPD was 63.76 years. The mean duration of the condition ranged from 173.47 days \[[@CR64]\] to 22.65 years \[[@CR67]\]. Fig. 1Flowchart of searching and screening for the studies

For the intervention of the Chinese herb formulas, MXSG was the most frequently reported treatment (15 trials), followed by WJ (12 trials), SBP (10 trials), QQHT (9 trials), DC (6 trials) and YBBX (3 trials). The formula ingredients and scientific names of herbs are listed in Additional file [3](#MOESM3){ref-type="media"}. In clinical practice, a formula is usually modified based on the original/classical formula according to the theory of Chinese medicine and a patient's clinical symptoms. The herb details of included studies are presented in Additional file [4](#MOESM4){ref-type="media"}. The treatment duration ranged from 5 days \[[@CR70]\] to 30 days \[[@CR20]\]. Only one study reported the follow-up period and investigated the recurrence after 1 month of treatment \[[@CR41]\].

FEV1 as the primary outcome was reported in 18 studies. The most frequently investigated outcome was the effective rate, which was evaluated in 52 studies. Other outcomes, such as hospital admissions and lengths of hospital stay, were not reported in any of the included studies. The additional characteristics of the included studies are summarized in Table [1](#Tab1){ref-type="table"}. Table 1Characteristics of included studiesStudy IDAge(year)\
(Mean ± SD)SeverityDuration of condition(year)\
((Mean ± SD))Sample size randomised/assessedinterventioncontrolTreatment durationoutcomesAdverse eventsZou HD 2015 \[[@CR20]\]I:65.32 ± 15.41; C:68.40 ± 16.221--4I:14.12 ± 5.14; C:15.24 ± 3.05I:50/50;C:50/50MXSG+RPRP30dFEV1;PaO2;PaCO2;ER0Zhou ZJ 2016 \[[@CR21]\]I:52.8 ± 4.7;C:52.7 ± 4.9NRNRI:40/40;C:40/40MXSG+RPRP7dERNRZhou YH 2015 \[[@CR22]\]I:67.73 ± 15.04;C:64.30 ± 14.19NRI:9.52 ± 3.33;C:10.8 ± 3.78I:44/44;C:40/40DC + RPRP3wFEV1;ER;mMRC0Zhou KL 2016 \[[@CR23]\]NRNRNRI:60/60;C:60/60MXSG+RPRP10dER;FEV1%NRZheng XM 2014 \[[@CR24]\]I:71.2 ± 8.01;C:72.30 ± 8.982--3I:4\~40;C:3\~30I:30/30;C:30/30SBP + RPRP10dFEV1%;PaO2;PaCO2;ER1Zhao WH 2007 \[[@CR25]\]I:67.37 ± 6.03;C:67.27 ± 5.751--3I: 3.62 ± 2.07;C: 3.13 ± 1.99I:30/30;C:30/30 mMRCWJ + RPRP10dER;PaO2;PaCO20Zhang LS 2011 \[[@CR26]\]67.7 ± 7.1NRNRI:40/40;C:40/40WJ + RPRP10dFEV1;FEV1%;6MWD18Zhang JH 2012 \[[@CR27]\]I:64.21 ± 6.12;C:64.30 ± 6.131--2I:10.01 ± 0.89;C:10.05 ± 0.32I:30/30;C:30/30QQHT+RPRP10dER;FEV1;FEV1%0Zhang JH 2006 \[[@CR29]\]I:65.21 ± 6.02;C:65.30 ± 6.131--2NRI:30/30;C:30/30WJ + RPRP10dER;FEV1;FEV1%;PaO2;PaCO20Zhang J 2011 \[[@CR28]\]I:55.4 ± 11.6;C:54.8 ± 8.541--2I:10\~30;C:10\~30I:50/50;C:50/50MXSG+RPRP2wER;FEV1%, PaO20Zhang CM 2012 \[[@CR30]\]I:55\~82;C:53\~842I:3\~30;C:3\~30I:44/44;C:44/44SBP + RPRP10dER0Zhang CL 2016 \[[@CR31]\]I:63.1 ± 10.5;C:64.5 ± 8.9NRI:15.3 ± 7.2;C:14.81 ± 8.3I:48/48;C:48/48YBBX+RPRP14dER;6MWDNRYe L 2011 \[[@CR32]\]NRNRNRI:30/30;C:30/30SBP + RPRP10dER;FEV1%;PaO2;PaCO2NRYang HW 2012 \[[@CR33]\]I:44\~78;C:45\~791--3I:4\~22;C:4\~20I:30/30;C:30/30MXSG+RPRP15dER;PaO2;PaCO20Xie WH 2009 \[[@CR34]\]I:45\~79;C:44\~801--3I:4\~20;C:3\~19I:42/42;C:40/40MXSG+RPRP15dER;FEV1NRXie JJ 2011 \[[@CR35]\]I:60 ± 3.55;C:61.5 ± 4.381--3I:5\~20;C:4\~21I:40/40;C:40/40YBBX+RPRP15dERNRWang XP 2015 \[[@CR36]\]I:58.32 ± 15.21;C:52.64 ± 15.74NRNRI:39/39;C:39/39MXSG+RPRP2wER;FEV1NRWang PC 2012 \[[@CR37]\]I:45\~82;C:47\~831--3I:3\~28;C:4\~25I:35/35;C:35/35YBBX+RPRP2wFEV1%NRWang CH 2015 \[[@CR38]\]NRNRNRI:30/30;C:30/30MXSG+RPRP10dERNRWang BH 2016 \[[@CR39]\]I:66.58 ± 2.5;C:66.42 ± 2.37NRI:8.92 ± 1.41;C:8.88 ± 1.34I:42/42;C:42/42WJ + RPRPNRER;FEV1;FEV1%;PaO2;PaCO2NRSun XS 2015 \[[@CR40]\]I:63.2 ± 9.7;C:61.9 ± 9.12--3I:10.3 ± 4.9;C:9.7 ± 4.6I:106/106;C:106/106MXSG+RPRP14dER;FEV1%NRSun JF 2012 \[[@CR41]\]NRNRNRI:31/31;C:31/31DC + RPRP14d;ERNRShi YY 2005 \[[@CR42]\]I:61.4 ± 6.8;C:59.5 ± 7.21--3I:16.34 ± 9.53;C:17.17 ± 10.22I:40/40;C:30/30WJ + RPRP14dER;FEV1;FEV1%;PaO2;PaCO20Ma DN 2013 \[[@CR43]\]I:71.74 ± 7.67;C:73.58 ± 5.311--4I:21.13 ± 12.20;C:21.58 ± 10.59I:40/39;C:40/40SBP + RPRP10dER;FEV1;FEV1%;PaO2;PaCO2NRLv T 2014 \[[@CR44]\]I:57.7 ± 2.6;C:57.4 ± 2.3NRI:10.5 ± 2.8;C:10.2 ± 2.4I:104/104;C:104/104QQHT+RPRP14dER;FEV1;FEV1%NRLiu X 2011 \[[@CR45]\]I:70.03 ± 6.22;C:70.90 ± 5.451--3I:9.03 ± 3.36;C:8.65 ± 2.47I:30/30;C:30/30DC + RPRP7dER;FEV1;FEV1%0Liu JB 2006 \[[@CR46]\]I:69.17 ± 7.53;C:69.05 ± 7.831--3I:16.86 ± 10.97;C:17.2 ± 11.25I:30/30;C:30/30WJ + RPRP10dER;FEV1%NRLin YZ 2014 \[[@CR47]\]I:64.1 ± 4.2;C:62.5 ± 3.12--3I:14.1 ± 3.5;C:13.7 ± 3.5I:102/102;C:90/90MXSG+RPRP7dER;FEV1%NRLin J 2011 \[[@CR48]\]I:70.2 ± 5.4;C:68.6 ± 4.2NRNRI:42/42;C:40/40DC + RPRP10dER;FEV1;FEV1%; PaO2; PaCO2NRLi ZR 2016 \[[@CR49]\]I:67.2;C:65.15NRI:6\~23;C:7\~25I:20/20;C:20/20SBP + RPRP10dPaO2; PaCO2NRLi YM 2012 \[[@CR50]\]I:61.89 ± 9.67;C:63.71 ± 8.121--4I:16.54 ± 12.65;C:15.93 ± 11.15I:40/40;C:40/40SBP + RPRP10dER;FEV1;FEV1%0Li Y 2013 \[[@CR51]\]I:62.17 ± 7.53;C:64.05 ± 7.831--3I:13.86 ± 10.97;C:17.2 ± 11.25I:30/30;C:30/30QQHT+RPRP10dER;PaO2;PaCO2NRLi XC 2014 \[[@CR52]\]I:68.11 ± 6.25;C:66.98 ± 6.70NRI:14.68 ± 6.32;C:15.95 ± 5.71I:32/31;C:32/30SBP + RPRP7dER;PaO2;PaCO20Li SQ 2013 \[[@CR53]\]I:65.3 ± 8.2;C:64.8 ± 8.6NRI:9.6 ± 4.2;C:9.2 ± 4.7I:40/40;C:40/40QQHT+RPRP10dER0Li L 2016 \[[@CR54]\]I:62.3 ± 11.2;C:63.1 ± 10.5NRI:11.20 ± 10.80;C:11.90 ± 10.90I:40/40;C:40/40MXSG+RPRP14dER0Li HM 2012 \[[@CR55]\]I:66.6 ± 6.62;C:65.50 ± 7.161--3I:12.6 ± 4.14;C:13.22 ± 4.28I:30/30;C:30/30QQHT+RPRP14dER;FEV1%0Ju P 2015 \[[@CR56]\]I:68.56 ± 6.43;C:70.32 ± 7.82NRI:20.27 ± 5.03;C:20.35 ± 5.72I:30/30;C:30/30QQHT+RPRP14dER;PaO2;PaCO2NRJing X 2011 \[[@CR57]\]I:55.63 ± 6.68;C:56.50 ± 5.892--3I:19.79 ± 7.28;C:18.21 ± 9.02I:24/24;C:24/24MXSG+RPRP2wER;FEV1%0Jing XL 2009 \[[@CR58]\]I:64.32 ± 5.53;C:63.27 ± 5.18NRNRI:37/37;C:37/37WJ + RPRP10dER;PaO2; PaCO20Jing XL 2007 \[[@CR59]\]I:66.3 ± 5.4;C:67.2 ± 4.41--2I:17.2 ± 3.5;C:13.5 ± 3.7I:30/30;C:30/30WJ + RPRP7dER;FEV1;PaO2;PaCO20Jiang H 2015 \[[@CR60]\]I:57.6 ± 10.2;C:58.1 ± 10.1NRI:10.5 ± 2.6;C:10.8 ± 2.7I:60/60;C:60/60MXSG+RPRP10dER;FEV1%NRJia JY 2016 \[[@CR61]\]I:60\~80;C:57\~70NRI:15\~25;C:13\~23I:32/32;C:32/32QQHT+RPRP14dER;FEV1;FEV1%;PaO2;PaCO2NRHuang XB 2013 \[[@CR62]\]I:62.00 ± 11.40;C:64.00 ± 12.30NRI:14.0 ± 7.10(m);C:15.0 ± 8.70(m)I:35/35;C:35/35SBP + RPRP10dER0Hua WS 2017 \[[@CR63]\]61.57 ± 6.54NR15.0 ± 3.0I:40/40;C:40/40MXSG+RPRP14dER;FEV1%NRHu J 2015 \[[@CR64]\]I:49.17 ± 12.88;C:43.84 ± 16.47NRI:173.47 ± 17.20(d);C:175.7 ± 15.75(d)I:80/80;C:80/80MXSG+RPRP1 mERNRGuo YY 2010 \[[@CR65]\]I:63.5;C:68.5NRI:8.9;C:9.3I:56/56;C:44/44WJ + RPRP15dERNRGuo F 2012 \[[@CR66]\]NRNRNRI:34/34;C:34/34SBP + RPRP10dER;PaO2;PaCO2NRGao X 2017 \[[@CR67]\]I:60.34 ± 8.27;C:62.44 ± 10.09NRI:22.65 ± 9.18;C:21.27 ± 9.97I:20/20;C:20/20DC + RPRP4wER;FEV1;6MWDNRFan HL 2003 \[[@CR68]\]I:65.87 ± 9.07;C:64.92 ± 8.961--3I:20.55 ± 5.84;C:20.06 ± 5.89I:57/57;C:50/50QQHT+RPRP10dERNRChen XM 2009 \[[@CR69]\]I:45\~90;C:47\~85NRNRI:31/31;C:31/31WJ + RPRP15dER;FEV1%;PaO2;PaCO20Chen XP 2016 \[[@CR70]\]I:69.54 ± 7.79;C:68.56 ± 6.27NRI:5\~10;C:5\~10I:65/65;C:62/62SBP + RPRP5dER2Chen HY 2012 \[[@CR71]\]I:72.07 ± 8.39;C:71.05 ± 7.932--3I:16.79 ± 10.53;C:17.2 ± 11.25I:30/30;C:30/30WJ + RPRP2wER;FEV1%;PaO2;PaCO2NRBi WZ 2016 \[[@CR72]\]I:72.32 ± 6.14;C:72.12 ± 6.21NRI:7.12 ± 2.14;C:7.26 ± 2.01I:44/44;C:44/44DC + RPRP14dER0Jing XL 2006 \[[@CR73]\]I:64.7 ± 5.2;C:64.2 ± 4.91--2I:13.2 ± 3.7;C:12.8 ± 3.9I:30/30;C:30/30WJ + RPRP10dER;FEV10Wang X 2010 \[[@CR74]\]I:47.7 ± 4.0;C:47.2 ± 3.641--2I:11.7 ± 2.85;C:12.6 ± 2.13I:30/30;C:30/30QQHT+RPRP14dER;FEV1%0*WJ* Weijing decoction, *SBP* Sangbaipi decoction, *YBBX* Yuebijiabanxia decoction, *DC* Dingchuan decoction, *QQHT* Qingqihuatan decoction, *MXSG* Maxingshigan decoction, *RP* Routine Pharmacotherapy, *NR* not reported, *mMRC* modified medical research council dyspnoea scale, *6MWD* 6-min walk distance, *m* month, *d* day, *w* week

Risk of bias {#Sec10}
------------

Nineteen studies (35%) reported an appropriate method for randomization, and allocation concealment was only reported in one study. None of the studies made efforts to blind the personnel or the participants. In terms of selective outcome reporting, four studies were assessed as being high risk because several of the pre-specified outcomes were not reported in their results. The risk of bias summary is listed in Fig. [2](#Fig2){ref-type="fig"}. Fig. 2Risk of bias graph

Treatment efficacy {#Sec11}
------------------

### FEV1 {#Sec12}

Eighteen studies involving 1432 participants evaluated the FEV1 of lung function among the five Chinese herb formulas. The pair-wise meta-analysis showed that only two formulas demonstrated superior effects, compared to the use of routine pharmacotherapy alone (WJ: MD 0.25, 95%CI (0.19, 0.30); QQHT: MD 0.34, 95%CI (0.10, 0.58)) (Table [2](#Tab2){ref-type="table"}). Network plots of the eligible comparisons for FEV1 are shown in Fig. [3](#Fig3){ref-type="fig"}. The results of the network meta-analysis revealed that SBP and MXSG were ranked the best in terms of FEV1 (Table [3](#Tab3){ref-type="table"}). However, the results should be interpreted with caution because the significant differences among these formulas were not detected. The SUCRA is presented in Fig. [4](#Fig4){ref-type="fig"}. Table 2Pair-wised random-effects meta-analysesInterventionFEV1PaO2PaCO2Effective rateNo. of studiesI/CMD,95% CINO. of studiesI/CMD,95% CINO. of studiesI/CMD,95% CINO. of studiesI/COR,95% CIWJ + RP vs RP6212/2020.25\[0.19,0.30\]8270/2609.90\[5.02,14.78\]8270/260−5.40\[− 8.33,-2.46\]10344/3223.60\[2.32,5.59\]SBP + RP vs RP279/800.40\[−0.63,1.43\]5154/1544.24\[1.10,7.38\]5154/154−5.33\[−9.68,-0.99\]11426/4233.56\[2.02,6.29\]YBBX + RP vs RP0NANA0NANA0NANA288/882.26\[0.85,5.99\]DC + RP vs RP4136/1300.05\[− 0.04,0.15\]142/405.20\[−0.15.10.55\]142/40−7.40\[−12.17,-2.63\]6211/2053.63\[1.91,6.89\]QQHT + RP vs RP3166/1660.34\[0.10,0.58\]392/9211.74\[4.21,19.27\]392/92−7.65\[−9.34,-5.95\]7222/2224.29\[2.18,8.46\]MXSG + RP vs RP3131/1290.38\[−0.05,0.80\]3130/1306.66\[−0.55,13.86\]280/80−8.80\[−10.21,-7.38\]13683/6692.77\[1.86,4.11\]I/C: Sample size of intervention/control groups. *MD* Mean Difference, *CI* Confidence interval, *OR* Odds Ratio Fig. 3Network diagram for FEV1 and effective rate Table 3Network meta-analysis of FEV1 and Effective rate Fig. 4SUCRA for FEV1

### PaO2 and PaCO2 {#Sec13}

In terms of arterial blood gases, both PaO2 and PaCO2 were evaluated among the five Chinese herb formulas. The beneficial effects on both outcomes were observed in the SBP, WJ and QQHT formulas by the use of the pair-wise meta-analyses (Table [2](#Tab2){ref-type="table"}). No significant changes were observed in PaO2 for MXSG and DC. The results of the NMA indicated that QQHT and WJ were more effective than SBP for improving PaO2. QQHT, WJ and MXSG may be optimal options for improving these two outcomes (Table [4](#Tab4){ref-type="table"}, Figs. [5](#Fig5){ref-type="fig"} and [6](#Fig6){ref-type="fig"}). Table 4Network meta-analysis of PaO2 and PaCO2 Fig. 5SUCRA for PaO2 Fig. 6SUCRA for PaCO2

### Effective rate {#Sec14}

A total of 47 studies were included in the comparisons of the effective rates among these six formulas. The effective rate was reported according to the Chinese medicine clinical research guidelines \[[@CR19]\]. The criteria for the effective rate were not able to be verified in five studies \[[@CR38], [@CR39], [@CR44], [@CR64], [@CR68]\]. These data were excluded from the analysis. The treatment effects that were estimated with the pair-wise random-effect meta-analysis showed that five of the six treatments had add-on favourable effects, compared to routine pharmacotherapy (WJ: OR 3.60, 95%CI (2.32,5.59); MXSG: OR 2.77, 95%CI (1.86,4.11); QQHT: OR 4.29, 95%CI (2.18,8.46); DC: OR 3.63, 95%CI (1.91,6.89); SBP: OR 3.56, 95%CI (2.02,6.29) and YBBX: OR 2.26, 95%CI (0.85,5.99)) (Table [2](#Tab2){ref-type="table"}). Network diagrams of the eligible comparisons are presented in Fig. [3](#Fig3){ref-type="fig"}. The results of the network meta-analysis showed significant differences in the five formulas, when compared to the use of pharmacotherapy alone (OR 3.13, 95%CrI (2.07,4.62) for MXSG; OR 3.92, 95%CrI (2.44,6.11) for WJ; OR 4.82, 95%CrI (2.26,9.30) for QQHT; OR 4.00, 95%CrI (2.18,7.03) for SBP and OR 3.70, 95%CrI (2.04,7.69) for DC) (Table [3](#Tab3){ref-type="table"}). The assessment for the YBBX formula did not demonstrate a significant difference (OR 2.71, 95%CrI (0.83, 6.74)). The efficacy ranking revealed that QQHT was the best treatment for the effective rate (Fig. [7](#Fig7){ref-type="fig"}). Fig. 7SUCRA for effective rate

### Safety {#Sec15}

Twenty-three studies reported no adverse events. One trial that evaluated the WJ formula reported mild events between the groups: liver and kidney dysfunction (4 cases) and indigestion (6 cases) in the treatment group, and liver and kidney dysfunction (4 cases) and indigestion (4 cases) in the control group \[[@CR26]\]. Mild digestive dysfunction was observed in two studies that assessed the efficacy of SBP \[[@CR24], [@CR70]\]. The causalities of these adverse events were not explored.

### Sensitivity analysis and publication bias {#Sec16}

A sensitivity analysis was performed by removing the trials that did not report appropriate methods for random sequence generations. Nineteen studies of the six Chinese herb formulas that evaluated the effective rate were included, and the results did not show major changes when comparing the results with the overall estimates (Additional file [5](#MOESM5){ref-type="media"}). QQHT and WJ may have better effects among these formulas, in terms of the effective rate. A further analysis for the other outcomes was not conducted, due to insufficient data. The publication bias was assessed in the studies that reported the effective rates. A visual inspection of the funnel plot showed that potential biases may have existed among these studies (Additional file [6](#MOESM6){ref-type="media"}).

Discussion {#Sec17}
==========

This network meta-analysis was conducted to compare the effects of six Chinese herb formulas combined with pharmacotherapy for the treatment of AECOPD. The results suggested that SBP and MXSG, as well as QQHT, appeared to be more effective for lung function improvement. QQHT, WJ and MXSG exhibited more favourable effects in terms of arterial blood gases (PaO2 and PaCO2). The effective rate was the sole outcome in evaluating all six of the Chinese herb formulas. The results indicated that QQHT may be the most effective formula, and consistent results were demonstrated in the sensitivity analysis. In summary, QQHT and MXSG might be the most effective formulas for the management of AECOPD.

For lung function, the results of the current pair-wise meta-analysis showed that only WJ and QQHT were observed to have significant changes on FEV1. In addition, only MXSG demonstrated a significant improvement in FEV1 compared with pharmacotherapy in the network meta-analysis. The possible reasons for these contradictory results are the small sample sizes of the included studies and the high heterogeneity that was observed among these studies. The results with wide confidence intervals may have changed from beneficial to non-beneficial if more studies were included. In addition, the NMA results showed that there was no significant difference among all five of the formulas. In addition to the small sample sizes of the included studies, another possible explanation was the similarity of the herb ingredients of these five formulas, such as *Ku Xing Ren* (*Semen Armeniacae Amarum*), *Ban Xia* (*Pinelliae Rhizoma*) and *Huang Qin* (*Scutellariae Radix*). These formulas or the active compositions of the herb ingredients have also shown common effects on anti-inflammation, anti-oxidative stress and immune function enhancement \[[@CR75]--[@CR78]\]. However, the ranking probabilities of these formulas could be explored according to the SUCRA. SBP, MXSG and QQHT seemed to be more effective than the other two formulas.

Strengths and limitations {#Sec18}
-------------------------

This study is the first comprehensive, systematic review to compare Chinese herb formulas for the treatment of AECOPD. The ranking of the commonly used formulas might be beneficial for clinical practice. Additionally, our study had some limitations. First, there were no head-to-head comparisons performed among these formulas. Second, some of the formulas were estimated by using small sample sizes and wide credible intervals, conclusions based on these studies are more likely to be changed by further research. Third, the formula ingredients of some studies varied substantially comparing with the fixed classical formulas, which may be difficult to replicate the results for other researchers. In addition, little information was reported for the use of routine pharmacotherapy among the included studies. In fact, the treatments also varied among the studies, in terms of antibiotic types, bronchodilators, doses and administration frequencies of these drugs. Several previous systematic reviews have compared the effectiveness of different treatment scenarios and have indicated different therapeutic advantages \[[@CR79]--[@CR81]\]. These differences might have introduced heterogeneity into our network meta-analysis. Therefore, the results should be interpreted with caution. Fourth, FEV1 as the primary outcome was only reported in eighteen studies and was evaluated in the five formulas. The results were still unreliable due to the small sample size. When considering that this outcome could provide objective measurements on the severity of the condition, future studies are suggested to include this outcome in order to reflect the clinically important outcomes. At last, methodology limitations existed in the included studies, such as inappropriate sequence generations, a lack of allocation concealment and a lack of blinding. Although we conducted a sensitivity analysis that focused on studies with low risks of bias on randomization, in order to explore the robustness of the results, the potential biases may affect the real therapeutic effects of these formulas due to the lack of blinding.

Implications for research {#Sec19}
-------------------------

Inadequate reporting in the current Chinese herb formula studies has affected the judgements about the efficacy and safety of Chinese Medicine (CM). For Chinese medicinal herbs, some may be referring to the multiple species \[[@CR82], [@CR83]\]. The absence of the herbal scientific names will introduce the difficulties to researchers in determining which kinds of species were observed. Moreover, this incompleteness may impede dissemination of information from clinical trials of CHM formulas and discourage the clinical practice \[[@CR84]\]. Future studies of Chinese herb formulas should comply with the recommendations of the CONSORT Extension for Chinese herbal medicine formulas \[[@CR84], [@CR85]\]. Efforts on the standardized reporting of clinical trials will promote data quality, research transparency, repeatability, generalization and readiness for synthesis, and these efforts may also help the authors in minimizing biases in research design from the start of a study. Moreover, in terms of comparing the safety of a Chinese herb formula, observational studies are also encouraged, especially real-world studies that use electrical medical records with long-term durations of follow-up.

In addition to the heterogeneity of the Chinese herb formulas, another major challenge in evaluating the clinical effects is the variety of the uses of pharmacotherapy in different clinical and research settings. Hence, future treatment scenarios should strictly follow the clinical guidelines, which will be beneficial in identifying the optimal treatments for guiding clinical practice.

Further research should be designed with the use of rigorous methodology, and the key outcome measures need to be reported, especially for FEV1, lengths of hospital stay and mortality. The effective rate, as a composite outcome, is defined as the improvement of clinical symptoms, including cough, phlegm and dyspnoea. However, inconsistent results are always produced, due to a lack of objective criteria; thus, clinical treatment effectiveness should be evaluated with the use of better validated outcome measures.

Conclusions {#Sec20}
===========

This comprehensive network meta-analysis showed that QQHT and MXSG might be the optimal Chinese herb formulas to combine with pharmacotherapy for the treatment of acute exacerbations of COPD. These six Chinese herb formulas seem to be similarly effective and significantly more effective than the use of pharmacotherapy alone in improvements of arterial blood gases and effective rates. However, the robustness of our findings may be affected due to the methodological limitations of the included studies. Further rigorous studies that include direct comparisons for these Chinese herb formulas, such as comparative effectiveness research, are encouraged to provide the most promising evidence for patients with AECOPD.

Additional files
================

 {#Sec21}

Additional file 1:The PRISMA-NMA checklist. (DOCX 29 kb) Additional file 2:Search terms. (DOCX 18 kb) Additional file 3:Summary of Chinese herb formulas. (DOCX 22 kb) Additional file 4:Herb details in included studies. (DOCX 26 kb) Additional file 5:Sensitivity analysis for effective rate. (PDF 1212 kb) Additional file 6:Funnel plot of effective rate. (PDF 15 kb)

AECOPD

:   Acute exacerbation of chronic obstructive pulmonary disease

AMED

:   Allied and Complementary Medicine Database

CBM

:   Chinese Biomedical Database

CENTRAL

:   Cochrane Central Register of Controlled Trials

CNKI

:   Chinese National Knowledge Infrastructure

COPD

:   Chronic obstructive pulmonary disease

CQVIP

:   Chongqing VIP Database

DC

:   Dingchuan decoction

MXSG

:   Maxingshigan decoction

OR

:   Odds ratio

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analysis

QQHT

:   Qingqihuatan decoction

SBP

:   Sangbaipi decoction

SUCRA

:   Surface under the cumulative ranking curve

WJ

:   Weijing decoction

YBBX

:   Yuebijiabanxia decoction
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